Biocure Technology Inc. CUREX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3,891.30% | 88,900.00% | -89.65% | 2,091.67% | -88.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3,891.30% | 88,900.00% | -89.65% | 2,091.67% | -88.78% |
| Operating Income | -3,891.30% | -88,900.00% | 89.65% | -2,091.67% | 88.78% |
| Income Before Tax | -10,271.61% | -18,309.09% | 86.38% | -413.64% | -5.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10,271.61% | -18,309.09% | 86.38% | -413.64% | -5.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10,271.61% | -18,309.09% | 86.38% | -413.64% | -5.44% |
| EBIT | -3,891.30% | -88,900.00% | 89.65% | -2,091.67% | 88.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6,023.08% | -9,925.00% | 93.01% | -2,000.00% | 7.14% |
| Normalized Basic EPS | -625.00% | -866.67% | 93.33% | -1,200.00% | 11.11% |
| EPS Diluted | -6,023.08% | -9,925.00% | 93.01% | -2,000.00% | 7.14% |
| Normalized Diluted EPS | -625.00% | -866.67% | 93.33% | -1,200.00% | 11.11% |
| Average Basic Shares Outstanding | 66.60% | 93.47% | 93.94% | -80.26% | 16.13% |
| Average Diluted Shares Outstanding | 66.60% | 93.47% | 93.94% | -80.26% | 16.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |